Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

UMRX - Unum Therapeutics Inc.

Close
2.35
0.010   0.426%

Share volume: 0
Last Updated: Mon 05 Oct 2020 10:00:00 PM CEST
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$2.34
0.01
0.43%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 37%
Dept financing 13%
Liquidity 15%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$2.35
P/E Ratio 
N/A
DAY RANGE
$2.32 - $2.41
EPS 
-$0.75
52 WEEK RANGE
$0.30 - $3.72
52 WEEK CHANGE
$63.19
MARKET CAP 
99.803 M
YIELD 
N/A
SHARES OUTSTANDING 
42.469 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$17,041,017
AVERAGE 10 VOLUME 
$279,462
AVERAGE 30 VOLUME 
$520,315
Company detail
CEO: Charles Wilson
Region: US
Website: http://www.unumrx.com
Employees: 72
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Recent news